Nuwae

Primary biliary cholangitis (PBC) is a slow-progressing autoimmune disease that often goes undetected until liver damage has already occurred. For years, treatment options have been limited, but two new therapies—Iqirvo and Livdelzi—are reshaping treatment for both patients and payers alike. In our latest edition of Nuwae insights, we explore the clinical benefits of these promising new drugs and what they mean for the future of PBC care. We’ll cover: ·  The current challenges in diagnosing and treating PBC ·  How Iqirvo and Livdelzi are offering earlier intervention and improved outcomes for patients ·  What payers should consider when navigating these more costly medications

As 2024 winds down, the Food and Drug Administration (FDA) is considering the approval of several highly-anticipated drugs with the potential to improve patient outcomes, reduce need for medical intervention and provide additional convenience. In our latest newsletter, we delve into three of these promising medications and why their impact on patient outcomes and healthcare costs make it crucial for payers to carefully evaluate their potential benefits and implications: Lebrikizumab, Garadacimab and Marstacimab. Read on to learn about these promising drugs, their mechanisms, clinical trial results and impact on both patients and payers. #fda #pharmanews

Are you prepared to navigate the evolving landscape of GLP-1 agonists and their impact on healthcare costs? In our latest newsletter, we delve into the current state of GLP-1 agonists and critical insights for payers, including: 💉 Current GLP-1 treatments 💰 Cost implications and generic introductions 💊 New treatments and indications in the pipeline Stay ahead of the curve and ensure your strategies are aligned with the latest developments in GLP-1 therapies today! #glp1s #pharma #glp1agonists

Exciting advancements in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) have emerged! In our latest newsletter, we delve into the newest treatment options and payer considerations, including: 💊 How current drugs are helping manage hemolysis and reducing the need for transfusions ☑️ New approvals of drugs like Fabhalta and Voydeya 🏥 Upcoming therapies, including RG6107, and the potential impact of biosimilars on treatment affordability. Learn about the latest updates, treatment options, and what this means for the future of PNH care below! #pnh #pharmanews #healthcare

Exciting pharmacy news! The FDA has approved Rezdiffra, a promising new treatment for Metabolic Dysfunction Associated Steatohepatitis (MASH), an often silent but severe stage of liver disease. MASH affects 1.5%-6.5% of adults and can lead to even more serious conditions, such as liver cancer.   Rezdiffra's approval offers new hope for those with MASH, and also poses new challenges and questions for payers, including prior authorization requirements, how increased diagnosis rates may cause a spike in GLP-1 agonist use, and treatment duration. In our latest newsletter, we break down all of this (and more)! Get the lowdown on MASH and Rezdiffra today. #MASH #rezdiffra #pharmanews

We've already seen several notable advancements in drug approvals from the FDA this year, and predict that some other heavy hitters will also be making a significant mark in the industry by year-end. Check out our list of 5 agents poised to make a powerful impact on payers and consumers this year. 💊 Want to learn more? Check out the full article: https://lnkd.in/eETTRhce #fda #pharmanews #pharmacybenefits

Nuwae believes there should be one price for a drug: the lowest price. We are industry veterans—specialists with deep experience and unique relationships which give us unique insight into the way these systems work and where they can be reformed in favor of better outcomes that benefit more people. #employeebenefits #pharmacybenefits

Our predictions for the Humira biosimilars market are proving accurate! A year after the introduction of biosimilars, AbbVie still commands 96% of the market, but the use of biosimilars is continuing to rise. Our whitepaper with Goodroot forecasted that biosimilars would capture up to 5% initially and grow to 20-25% by 2026. https://hubs.li/Q02vcQpd0 ❓Why did #Humira continue to dominate? Our experts say that's because it was already included on formularies at a parity position by the "big 3" PBMs that control 80% of the market. As other #biosimilars are now being prioritized in some of these PBMs, we predict that biosimilars will rise dramatically over the rest of the year. Stay tuned as we continue to monitor these developments and read our full whitepaper at: https://hubs.li/Q02vcGfj0

Happy #NationalSmallBusinessWeek from the Goodroot community of companies! Small businesses are the backbone of our country, and we are proud to work alongside so many each and every day. Thank you to all small business owners for your hard work, innovation and dedication—we are incredibly grateful for all that you do. 🫶 #smallbusiness #entrepreneurship #NSBW

In 2023, using GLP-1s for weight loss captured the public's attention. With this rise in popularity has come a major shortage of these drugs, impacting the people who need them for diabetes treatment and necessary weight loss. Scroll through to get the breakdown of what's happening, and get the full scoop on the current state of GLP-1s in our updated guide with Goodroot: https://hubs.li/Q02tNmFQ0 #glp1s #weightlossdrugs #pharma